The Weill Cornell Breast Center would like to invite all patients who meet the following criteria to contact us about free genetic testing for the BRCA1 and BRCA2 mutations:
- Metastatic breast cancer
- Her2neu negative breast cancer
- No more than two prior regimens of chemotherapy in the metastatic setting
If you meet the criteria above, you may be eligible for free genetic testing. If you test positive for the gene mutation, you may be eligible to participate in one of our treatment trials.
Please contact Marta Cobham, RN at 212.821.0780 or email@example.com or Naomi Kornhauser, MPH at firstname.lastname@example.org for more information.
Click to enlarge poster
In a poster presentation this week at the American Society of Clinical Oncology (ASCO) conference, researchers presented results from a nationwide study assessing a PARP inhibitor in BRCA-associated breast cancer. Dr. Tessa Cigler is the principal investigator of the study, “ABT-888 (veliparib) in combination with carboplatin in patients with stage IV BRCA-associated breast cancer,” at the Weill Cornell Breast Center.
Platinum and PARP inhibitors have demonstrated activity when used as single agent therapy in BRCA-associated breast cancer. However, there is limited data on using the two classes of medications together.
The study enrolled 22 women with BRCA-associated stage IV breast cancer to compare a combination of carboplatin (platinum-based chemotherapy) and ABT-888 (veliparib, a PARP inhibitor) vs. single agent ABT-888, when ABT-88 is given every day.
The investigators found that the combination of caboplatin and ABT-888 is feasible, and, in preliminary analysis, the response and clinical benefit rates and duration are encouraging. The authors write that the results provide “justification to proceed with a planned phase II randomized single agent versus combination trial.”
Click here to read the published abstract.